Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Inventory (2021 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Inventory readings, the most recent being $73.1 million for Q1 2026.

  • On a quarterly basis, Inventory rose 231.42% to $73.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $73.1 million, a 231.42% increase, with the full-year FY2025 number at $54.9 million, up 108.22% from a year prior.
  • Inventory hit $73.1 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $54.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $73.1 million in Q1 2026 to a low of $13.2 million in Q1 2022.
  • Median Inventory over the past 5 years was $26.4 million (2024), compared with a mean of $31.2 million.
  • Biggest five-year swings in Inventory: surged 504.07% in 2022 and later decreased 19.1% in 2025.
  • Kiniksa Pharmaceuticals International's Inventory stood at $21.6 million in 2022, then surged by 44.09% to $31.1 million in 2023, then decreased by 15.29% to $26.4 million in 2024, then surged by 108.22% to $54.9 million in 2025, then skyrocketed by 33.24% to $73.1 million in 2026.
  • The last three reported values for Inventory were $73.1 million (Q1 2026), $54.9 million (Q4 2025), and $41.4 million (Q3 2025) per Business Quant data.